Drug Patent List
First Filer Exclusivity TimelineNew
Newsletter
Weekly Digest

Pharsight

Gilead Sciences Drug Patent Portfolio

Gilead Sciences's Family Patents


Family Patents





Clinical Trials

Recent Clinical Trials by Gilead Sciences:

Title Lead Sponsor Collaborators Status Phases
Clinical Trials
Study of Bictegravir/Emtricitabine/Tenofovir Alafenamide Fixed Dose Combination in Adolescents and Children With Human Immunodeficiency Virus-1 Gilead Sciences NA ACTIVE NOT RECRUITING
(Sep 1, 2026)
PHASE2, PHASE3
Study of Sacituzumab Govitecan Combinations in First-line Treatment of Participants With Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC) Gilead Sciences NA ACTIVE NOT RECRUITING
(Sep 1, 2026)
PHASE2
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63) Gilead Sciences NA RECRUITING
(Sep 1, 2026)
PHASE3
Study of Novel Treatment Combination Therapies in Participants With Head and Neck Squamous Cell Carcinoma Regardless of PD-L1 Expression Status; Substudy-01 Gilead Sciences NA ACTIVE NOT RECRUITING
(Sep 1, 2026)
PHASE2
Study of Denikitug (GS-1811) Given Alone or With Nivolumab or Chemotherapy in Adults With Metastatic Gastric, Gastroesophageal Junction (GEJ), and Esophageal Adenocarcinomas Gilead Sciences NA RECRUITING
(Sep 1, 2026)
PHASE2
Study of an Injectable Regimen of GS-3242 With Lenacapavir Compared to Biktarvy in People New to HIV-1 Treatment Gilead Sciences NA RECRUITING
(Sep 1, 2026)
PHASE2, PHASE3
Study to Evaluate the Safety and Efficacy of Emtricitabine and Tenofovir Alafenamide (F/TAF) Fixed-Dose Combination Once Daily for Pre-Exposure Prophylaxis in Men and Transgender Women Who Have Sex With Men and Are At Risk of HIV-1 Infection Gilead Sciences NA TERMINATED
(Aug 1, 2026)
PHASE3
Study of Sacituzumab Govitecan in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread Gilead Sciences NA ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE2
Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated Regimen Gilead Sciences NA ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE2, PHASE3
Study of Lenacapavir and Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF) in Prevention of HIV in Cisgender Women in the United States (HPTN 102) Gilead Sciences NA ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE2
Study of Lenacapavir and Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF) for Prevention of HIV in People Who Inject Drugs (HPTN 103) Gilead Sciences NA ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE2
Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer Gilead Sciences NA RECRUITING
(Aug 1, 2026)
PHASE3
Study of Bictegravir/Emtricitabine/Tenofovir Alafenamide in Newborns Exposed to HIV Gilead Sciences NA ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE1
Study of GS-5319 Given Alone or in Combination in Adults With Solid Tumors Gilead Sciences NA RECRUITING
(Aug 1, 2026)
PHASE1
A Study of GS-3242 in Combination With Lenacapavir Versus Biktarvy in Virologically Suppressed People With HIV-1 Gilead Sciences NA RECRUITING
(Aug 1, 2026)
PHASE2
Pre-Exposure Prophylaxis Study of Lenacapavir and Emtricitabine/Tenofovir Alafenamide in Adolescent Girls and Young Women at Risk of HIV Infection Gilead Sciences NA ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE3
Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GS-9716 as Monotherapy and in Combination With Anticancer Therapies in Adults With Solid Malignancies Gilead Sciences NA TERMINATED
(Jul 1, 2026)
PHASE1
Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer After Platinum-Based Chemotherapy and Immunotherapy (ASCENT-GYN-01/GOG-3104/ENGOT-en26) Gilead Sciences NA ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE3
Study of Denikitug (GS-1811) Given Alone or With Nivolumab or With Chemotherapy in Adults With Advanced Colorectal Cancer Gilead Sciences NA RECRUITING
(Jul 1, 2026)
PHASE2
Study of GS-2426 in Participants With Advanced Solid Tumors Gilead Sciences NA RECRUITING
(Jul 1, 2026)
PHASE1
Study of Lenacapavir, Teropavimab, and Zinlirvimab in Virologically Suppressed Adults With HIV-1 on Stable Oral Treatment Regimens Gilead Sciences NA RECRUITING
(Jul 1, 2026)
PHASE3
Intended to Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects With Primary Biliary Cholangitis (PBC) Gilead Sciences NA COMPLETED
(Jun 1, 2026)
PHASE3
Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With Biktarvy Gilead Sciences NA ACTIVE NOT RECRUITING
(Jun 1, 2026)
PHASE3
Study of Lenacapavir Taken Twice a Year for HIV Pre-Exposure Prophylaxis (PrEP) Gilead Sciences NA ACTIVE NOT RECRUITING
(Jun 1, 2026)
PHASE2
Study of GS-4571 in Healthy Participants, Nondiabetic Obese Participants, and Nonobese Participants With Type 2 Diabetes Mellitus (T2DM) Gilead Sciences NA RECRUITING
(Jun 1, 2026)
PHASE1
Study of Sacituzumab Govitecan Versus Physician's Choice of Treatment in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread Gilead Sciences NA COMPLETED
(May 1, 2026)
PHASE3
Study of Novel Treatment Combinations in Patients With Lung Cancer Gilead Sciences NA ACTIVE NOT RECRUITING
(May 1, 2026)
PHASE2
Study With Various Immunotherapy Treatments in Participants With Lung Cancer Gilead Sciences NA ACTIVE NOT RECRUITING
(May 1, 2026)
PHASE2
Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Standard of Care in Virologically Suppressed People With HIV-1 Gilead Sciences NA ACTIVE NOT RECRUITING
(May 1, 2026)
PHASE3
Study of GS-3242 in Participants With HIV-1; Substudy-05 Gilead Sciences NA COMPLETED
(May 1, 2026)
PHASE1
Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV Gilead Sciences NA ACTIVE NOT RECRUITING
(Apr 1, 2026)
PHASE2, PHASE3
Study of Sacituzumab Govitecan (SG) Versus Docetaxel in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) Gilead Sciences NA ACTIVE NOT RECRUITING
(Apr 1, 2026)
PHASE3
Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer Gilead Sciences NA ACTIVE NOT RECRUITING
(Apr 1, 2026)
PHASE3
A Study of Teropavimab and Zinlirvimab in Combination With Capsid Inhibitor Lenacapavir in Virologically Suppressed Adults With HIV-1 Infection Gilead Sciences NA ACTIVE NOT RECRUITING
(Apr 1, 2026)
PHASE2
Study of Oral Weekly Lepetegravir (Formerly GS-1720) and Lenacapavir Pacfosacil (Formerly GS-4182) Versus Biktarvy in People With HIV-1 Who Are Virologically Suppressed Gilead Sciences NA ACTIVE NOT RECRUITING
(Apr 1, 2026)
PHASE2, PHASE3
Study of Oral Weekly GS-1720 and GS-4182 Compared With Biktarvy in People With HIV-1 Who Have Not Been Treated Gilead Sciences NA TERMINATED
(Apr 1, 2026)
PHASE2, PHASE3
Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed People With HIV-1 Gilead Sciences NA ACTIVE NOT RECRUITING
(Apr 1, 2026)
PHASE3


Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List